Cutting Edge: Reversal of Murine Lupus Nephritis with CTLA4Ig and Cyclophosphamide
作者： David I. Daikh , David Wofsy
DOI: 10.4049/JIMMUNOL.166.5.2913
关键词: Autoantibody 、 Immunoglobulin G 、 Pharmacology 、 Lupus nephritis 、 Proteinuria 、 Cyclophosphamide 、 Endocrinology 、 Abatacept 、 Medicine 、 Nephritis 、 Internal medicine 、 Antigen
摘要: Cyclophosphamide (CTX) prevents progression of nephritis and prolongs survival in (NZB x NZW)F(1) (B/W) mice is used to treat humans with lupus nephritis. To compare the efficacy CTLA4Ig CTX determine whether there an incremental benefit combining CTX, we treated B/W CTLA4Ig, or both agents. In mild renal disease, treatment delayed onset proteinuria prolonged all groups. advanced agents reduced 71% mice, whereas either agent alone had no such improvement. Survival was also markedly improved among Thus, combination more effective than reducing disease prolonging This striking reversal unprecedented animal models SLE.
elsevier.com
jimmunol.org参考文章(33)
T. P. CASEY, Immunosuppression by Cyclophosphamide in NZB X NZW Mice With Lupus Nephritis Blood. ,vol. 32, pp. 436- 444 ,(1968) , 10.1182/BLOOD.V32.3.436.436
Gary L Baker, Leslie E Kahl, Benny C Zee, Bertrand L Stolzer, Amrit K Agarwal, Thomas A Medsger Jr, None, Malignancy following treatment of rheumatoid arthritis with cyclophosphamide: Long-term case-control follow-up study The American Journal of Medicine. ,vol. 83, pp. 1- 9 ,(1987) , 10.1016/0002-9343(87)90490-6
Susan L. Kalled, David W. Thomas, Syamal K. Datta, Anne H. Cutler, Anti-CD40 Ligand Antibody Treatment of SNF1 Mice with Established Nephritis: Preservation of Kidney Function Journal of Immunology. ,vol. 160, pp. 2158- 2165 ,(1998)
G M Leytze, P M Wallace, P S Linsley, J N Rodgers, J S Johnson, Induction and reversal of long-lived specific unresponsiveness to a T-dependent antigen following CTLA4Ig treatment. Journal of Immunology. ,vol. 154, pp. 5885- 5895 ,(1995)
Prabhakar Baliga, Kenneth D. Chavin, Lihui Qin, Jennifer Woodward, Jixun Lin, Peter S. Linsley, Jonathan S. Bromberg, CTLA4Ig prolongs allograft survival while suppressing cell-mediated immunity. Transplantation. ,vol. 58, pp. 1082- 1090 ,(1994) , 10.1097/00007890-199411000-00005
D.T. Boumpas, H.A. Austin, J.E. Balow, E.M. Vaughan, C.H. Yarboro, J.H. Klippel, A.D. Steinberg, Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis The Lancet. ,vol. 340, pp. 741- 745 ,(1992) , 10.1016/0140-6736(92)92292-N
R.A. Luqmani, R.G. Palmer, P.A. Bacon, Azathioprine, cyclophosphamide and chlorambucil. Baillière's clinical rheumatology. ,vol. 4, pp. 595- 619 ,(1990) , 10.1016/S0950-3579(05)80009-3
Jeffrey A. Bluestone, New perspectives of C1328-137-mediated T cell costimulation Immunity. ,vol. 2, pp. 555- 559 ,(1995) , 10.1016/1074-7613(95)90000-4
Alfred D. Steinberg, Michael C. Gelfand, John A. Hardin, David T. Lowenthal, Therapeutic studies in NZB/W MICE Arthritis & Rheumatism. ,vol. 18, pp. 9- 14 ,(1975) , 10.1002/ART.1780180102
DAVID B. HELLMANN, MICHELLE PETRI, QUINN WHITING-OʼKEEFE, Fatal infections in systemic lupus erythematosus: the role of opportunistic organisms. Medicine. ,vol. 66, pp. 341- 348 ,(1987) , 10.1097/00005792-198709000-00002